share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股變動聲明
SEC announcement ·  03/22 17:48
Moomoo AI 已提取核心訊息
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
2024年3月20日，CRISPR Therapeutics AG的首席財務官拉朱·普拉薩德參與了與該公司股票的交易。公告中未披露交易的具體細節，例如行動類型、狀態、股票數量、股票性質、交易價格和交易後持有量。這些信息對於投資者了解其投資的潛在影響以及公司高管對未來的信心至關重要。
2024年3月20日，CRISPR Therapeutics AG的首席財務官拉朱·普拉薩德參與了與該公司股票的交易。公告中未披露交易的具體細節，例如行動類型、狀態、股票數量、股票性質、交易價格和交易後持有量。這些信息對於投資者了解其投資的潛在影響以及公司高管對未來的信心至關重要。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息